Table 3.

Demographic and clinical features of patients.

		N (47)	%
Age*		53 ± 13	27–80
Body mass index*		29.6 ± 5.5	20.0–41.6
BRCA mutation		9	19.1
Comorbidities		21	43.7
History of drug allergy		6	12.7
Histology	Serous (high-grade)	42	89.4
	Non-serous	5	10,6
Desensitization decide	History of prior HSR	24	51
	Positive CP skin test	23	49
Stage at diagnosis	1–2	4	8.6
	3–4	43	91.4
Neo-adjuvant chemotherapy	Yes	12	25.5
	No	35	75
Number of CP cycle develop HSR: median (range)		9.6 ± 2.3	7–14
Cycles of desensitization treatment		11.0 ± 8.5	3–36
Success desensitization rate		478 of total 496 cycles, 96.3%

CP = carboplatin, HSR = hypersensitivity reaction.